• Alterity Therapeutics highlighted a newly published, peer-reviewed NeuroImage study supporting quantitative susceptibility mapping MRI as an imaging biomarker for Multiple System Atrophy, with results already presented in the publication.
• The analysis from the bioMUSE natural history study indicates the imaging method can detect disease-specific brain iron accumulation, help distinguish MSA from Parkinson’s disease, and track clinical severity, including in early-stage disease.
• Alterity said it previously used the approach in its Phase 2 trial of lead candidate ATH434, citing improved diagnostic accuracy and objective evidence of target engagement.
• Company positioned the findings as supportive of earlier diagnosis strategies and as a tool to evaluate iron-modulating therapies in MSA, including ATH434.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.